Dergiler / Eurasian Journal of Emergency Medicine / 2017 / Cilt: 16 - Sayı: 2

Evaluation of the VKORC 1 and CYP2C9 Gene Polymorphisms and Their Effects on the Emergency Complications in the Patients Using Warfarin

Sayfa
65–69
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

These genes have no effect on bleeding and frequent applications of emergency service

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: We aimed to evaluate the effects of genetic polymorphisms on the frequency of application to the emergency service and on the complications with use of warfarin in this study.
📊
Temel Bulgular & Veri:Two groups were composed: one group of 40 patients who used warfarin and with international normalized ratios (INRs) >=3.5 IU and a second group of 30 control group patients with normal INR levels.
💡
Sonuç & Katkı:These genes have no effect on bleeding and frequent applications of emergency service
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Aim: We aimed to evaluate the effects of genetic polymorphisms on the frequency of application to the emergency service and on the complications with use of warfarin in this study. Materials and Methods: Seventy patients were included in the study. Two groups were composed: one group of 40 patients who used warfarin and with international normalized ratios (INRs) >=3.5 IU and a second group of 30 control group patients with normal INR levels. Blood samples were examined through the warfarin dosage sensitivity test. Results: VKORC 1 heterozygote type AG was the most frequently seen allele in 17 of the haplotype patients (42.5%), in 12 of the control group patients (40%), in 21 of the CYP2C9 *1/*1 patients (52.5%), and in 17 of the CYP2C9 *1/*1 control group patients. No statistically significant difference was identified between the groups (p>0.05). No statistically significant relationship was established as regards the frequency of emergency service visits and bleeding complications with CYP2C9 and VKORC 1 genes. Conclusion: The most common haplotypes VKORC 1 heterozygote type AG and CYP2C9 *1/*1. No relationship was identified between INR levels and VKORC 1 and CYP2C9 haplotypes. These genes have no effect on bleeding and frequent applications of emergency service

🔖

Bu Makaleye Atıf Yap

EMEKTAR, E., ÇEVİK, Y., ÇORBACIOĞLU, Ş. K., KARABULUT, A. E., YARDIM, O. (2022). Evaluation of the VKORC 1 and CYP2C9 Gene Polymorphisms and Their Effects on the Emergency Complications in the Patients Using Warfarin. Eurasian Journal of Emergency Medicine, Cilt: 16 - Sayı: 2, 65–69. https://ajindex.com/articles/508083

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Goldstein JA. Clinical Relevance of Genetic Polymorphisms in Human CYP'C Subfamily. Br J Clin Pharmacol 2001; 52: 349-55. [CrossRef] Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagula- tion factor deficiency Type 2. Nature 2004; 427: 537-41. [CrossRef] Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, et al. Hydroxylation of Warfarin by Human cDNA-expressed Cytochrome P450: A Role for P4502C9 in The Etiology of (S)- warfarin Drug İnterac- tions. Chem Res Toxicol 1992; 5: 54-9. [CrossRef] Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic Analysis of The Human Cytchrome P450 CYP2C9 Locus. Pharmacogenetics 1996; 6: 429-39. [CrossRef] You M, Kenji N, Yoshiki S. Clinical Significance of Combined CYP2C9 and VKORC1 Genotypes in Japanese Patients Requiring Warfarin. Int Heart J 2011; 52: 44-9. [CrossRef] Yang L, Ge W, Yu F, Zhu H. Impact of VKORC1 gene polymorphism on inter in- dividual and inter ethnic warfarin dosage requirement- A systematic review and meta analysis. Thrombosis Research 2010; 125: 159-66. [CrossRef] Wilke RA, Berg RL, Vidaillet HJ, Caldwell MD, Burmester JK, Hillman MA. Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin ther- apy. Clin Med Res 2005; 3: 207-13. [CrossRef] Aithal GP, Day CP, Kesteven PJ, Daly AK. Assosiation of Polymorphisms in The Cytochrome P450 CYP2C9 with warfarin dose requirment and risk of bleeding complications. Lancet 1999; 353: 717-9. [CrossRef] Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8. [CrossRef] Ngow HA, WanKhairina WMN, Teh LK, Lee WL, Harun R, Ismail R, et al. CY- P2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia. Singapore Med J 2009; 50: 490-3.
  2. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnetTM systemic review and meta-analysis. Genet Med 2005; 7: 97-104. [CrossRef] Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements- a systemic review and meta-analysis. Eur J Clin Pharmacol 2009; 65: 365-75. [CrossRef] Özer N, Cam N, Tanyürek B, Özer S, Uyarel H, Öz D, et al. The impact of CYP2C